Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study for Patients With Schizophrenia

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: August 24, 2007
Last updated: October 16, 2009
Last verified: October 2009
The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.

Condition Intervention Phase
Drug: LY2140023
Drug: Olanzapine
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Inpatient, Phase 2, Double-blind, Placebo-Controlled Dose Ranging Study of LY2140023 in Patients With DSM-IV Schizophrenia

Resource links provided by NLM:

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Positive and Negative Syndrome Scale (PANSS) total score [ Time Frame: over 4 weeks of treatment ]

Secondary Outcome Measures:
  • PANSS subscores: positive subscore; negative subscore; general psychopathology subscore and cognitive subscore [ Time Frame: over 4 weeks of treatment ]
  • Clinical Global Impression-Severity (CGI-S) [ Time Frame: over 4 weeks of treatment ]
  • Drug Attitude Inventory-10 (DAI-10) [ Time Frame: over 4 weeks of treatment ]
  • Response and Remission Rates [ Time Frame: over 4 weeks of treatment ]
  • Assessment of Cognition in Schizophrenia (BACS) Symbol Coding Task [ Time Frame: over 4 weeks of treatment ]
  • Montgomery-Asberg Depression RatingScale (MADRS) [ Time Frame: over 4 weeks of treatment ]
  • Safety and Tolerability [ Time Frame: over 4 weeks of treatment ]
  • Pharmacokinetics [ Time Frame: over 4 weeks of treatment ]

Enrollment: 654
Study Start Date: September 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
160mg of LY2140023, taken orally as 80mg twice daily, for up to 4 weeks.
Drug: LY2140023
80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
Experimental: 2
80mg of LY2140023, taken orally as 40mg twice daily, for up to 4 weeks.
Drug: LY2140023
40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
Experimental: 3
40mg of LY2140023, taken orally as 20mg twice daily, for up to 4 weeks.
Drug: LY2140023
20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
Experimental: 4
10mg of LY2140023, taken orally as 5mg twice daily, for up to 4 weeks.
Drug: LY2140023
5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
Placebo Comparator: 5
Placebo of LY2140023, taken orally twice daily, for up to 4 weeks.
Drug: Placebo
Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
Active Comparator: 6
Placebo, taken orally every morning, followed by Olanzapine 15mg taken orally every evening for up to 4 weeks.
Drug: Olanzapine
10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
Drug: Placebo
Taken PO (by mouth) QAM (every morning) for up to 4 weeks.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Some Inclusion Criteria:

  • Patients must have a diagnosis of Schizophrenia as defined in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (Disorganized, 295.10; Catatonic, 295.20; Paranoid, 295.30; Residual, 295.60; or Undifferentiated, 295.90) and confirmed by the Structured Clinical Interview for DSM-IV (SCID).
  • Patients must meet the following psychopathologic severity criteria at Visit 1: Brief Psychiatric Rating Scale (BPRS) total score, extracted from the Positive and Negative Syndrome Scale (PANSS), of at least 45 (18-item version, in which 1 indicates "absent" and 7 indicates "severe"). In addition, item scores of at least 4 (moderate) will be required on 2 of the following BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and/or unusual thought content.
  • Patients must receive a rating of 4 (moderately ill) or greater on the Clinical Global Impression-Severity (CGI-S) scale at Visit 1.
  • Patients in whom, in the opinion of the investigator, a switch to another antipsychotic medication or initiation of an antipsychotic medication is acutely indicated.

Some Exclusion Criteria:

  • Patients in whom treatment with olanzapine or placebo is relatively or absolutely clinically contraindicated.
  • Patients who have a history of inadequate response to an adequate treatment trial with olanzapine, in the opinion of the investigator.
  • Patients who have received treatment with olanzapine within 6 weeks prior to Visit 1.
  • Patients who have received treatment with clozapine at doses greater than 200 mg daily within 12 months prior to Visit 1, or who have received any clozapine at all during the month before Visit 1.
  • Patients who have a history of an inadequate response, in the opinion of the investigator, to 2 or more adequate antipsychotic medication trials of at least 8 weeks duration in the past 12 months prior to Visit 1.
  • Patients with acute, serious, or unstable medical conditions, including (but not limited to) inadequately controlled diabetes (hemoglobin A1c (HbA1c) 8%), severe hypertriglyceridemia (fasting triglycerides 5.6 mmol/L, recent cerebrovascular accidents, serious acute systemic infection or immunologic disease, unstable cardiovascular disorders (including ischemic heart disease), malnutrition, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, or hematologic diseases.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00520923

  Show 35 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Chief Medical Officer, Eli Lilly Identifier: NCT00520923     History of Changes
Other Study ID Numbers: 11757
Study First Received: August 24, 2007
Last Updated: October 16, 2009

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents processed this record on May 23, 2017